Qinlock demonstrated a powerful PFS benefit2
Qinlock demonstrated superior median PFS: 6.3 months vs 1.0 month with placebo (P<0.0001)2*
Primary endpoint: PFS2

*Double-blind period.
- Qinlock PFS results were generally consistent across all assessed patient subgroups4
Learn more about this powerful PFS benefit from a Qinlock representative.
Estimated PFS at 6, 9, and 12 months in Invictus5
Estimated landmark PFS | Qinlock | Placebo |
---|---|---|
(n=85) | (n=44) | |
6-months PFS (95% CI) | 51.0% (39.4-61.4%) | 3.2% (0.2-13.8%) |
9-months PFS (95% CI) | 34.4% (22.9-46.2%) | NE (NE, NE) |
12-months PFS (95% CI) | 21.0% (9.0, 36.3) | NE (NE, NE) |
NE=not estimable.
Key Secondary Endpoint
Objective response rate (ORR) by BICR: 9.4% with QINLOCK vs 0.0% with placebo (P=0.0504).2,3†
- The median duration of response had not been reached at the study cutoff date3
†All responses were partial responses.
Exploratory Analysis
- 66% of Qinlock‑treated patients experienced stable disease ≥6 weeks vs 20% with placebo3
Overall survival (OS) with Qinlock: 15.1 months vs 6.6 months with placebo2,3‡
SECONDARY ENDPOINT: OS3

‡Not evaluated for statistical significance as a result of the sequential testing procedure used for the secondary endpoints of ORR and OS.2
Placebo crossover: median OS results4
Exploratory Analysis4§
- Tumor assessments were conducted after each 4‑week treatment cycle through the first 4 cycles2
- Upon disease progression, patients on placebo could cross over to receive open-label Qinlock2
- At study cutoff date, 66% of patients had crossed over from the placebo arm and received ≥1 dose of Qinlock2
§This analysis was exploratory in nature; it did not control for type 1 error and was not powered to determine treatment effect in any subgroup.


The Qinlock safety profile was established across a broad range of patients in the Invictus trial2,3
Rates of discontinuation and dose modification due to adverse reactions were similar between Qinlock and placebo2,6
See How Qinlock Works
Qinlock is the first and only switch-control kinase inhibitor2,7
Learn About The MOAOnce-daily Dosing
Qinlock is dosed orally, once daily, with or without food2
Dosing & Administration